Related Experiment Video

Updated: May 31, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung

Pei Pei Gan1, Joshua A McCarroll, Frances L Byrne

  • 1Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, Australia.

Plos One
|July 9, 2011
PubMed

Insights

Specific beta-tubulin isotypes influence sensitivity to epothilone B, a microtubule stabilizing agent. Knockdown of betaIII-tubulin increased sensitivity, while betaIVb-tubulin knockdown decreased sensitivity in non-small cell lung cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epothilones are novel microtubule-stabilizing agents with significant preclinical and clinical potential.
  • Understanding factors that influence intrinsic sensitivity to epothilones is crucial for optimizing their therapeutic use.
  • The specific beta-tubulin isotypes targeted by epothilones and their role in cellular response remain incompletely understood.

Purpose of the Study:

  • To investigate the functional significance of specific beta-tubulin isotypes (βII, βIII, βIVb) in determining intrinsic sensitivity to epothilone B.
  • To elucidate the impact of beta-tubulin isotype modulation on epothilone B efficacy in non-small cell lung cancer (NSCLC) cell lines.

Main Methods:

  • Utilized siRNA gene knockdown to specifically target βII-, βIII-, or βIVb-tubulin in NCI-H460 and Calu-6 NSCLC cell lines.
  • Performed drug-treated clonogenic assays to assess sensitivity to epothilone B.
  • Conducted cell cycle analysis and measured apoptosis (caspase 3/7 activity, Annexin-V staining) to evaluate cellular response.

Main Results:

  • Knockdown of βII-tubulin did not alter epothilone B sensitivity.
  • Knockdown of βIII-tubulin significantly increased sensitivity to epothilone B, leading to higher cell death and apoptosis.
  • Knockdown of βIVb-tubulin significantly decreased sensitivity to epothilone B, with reduced G(2)-M cell cycle accumulation and higher required concentrations for apoptosis induction.

Conclusions:

  • Specific β-tubulin isotypes play a critical role in modulating cellular sensitivity to epothilone B.
  • βIII-tubulin expression may be a predictive marker for response to epothilone B therapy.
  • βIVb-tubulin may confer resistance to epothilone B, suggesting potential mechanisms for differential drug response in cancer treatment.

More Related Videos

Optimizing Tubulin Yield from Porcine Brain Tissue06:30

Optimizing Tubulin Yield from Porcine Brain Tissue

Published on: October 11, 2024

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...